Standout Papers
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016)
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018)
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020)
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis (2021)
Immediate Impact
2 by Nobel laureates 8 from Science/Nature 60 standout
Citing Papers
Natural killer cell therapies
2024 StandoutNature
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
2024 Standout
Works of Marina Tschaika being referenced
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
2020 Standout
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Marina Tschaika | 1617 | 661 | 512 | 653 | 37 | 2.2k | |
| Catherine Julié | 1647 | 611 | 540 | 683 | 68 | 2.3k | |
| Todd S. Crocenzi | 1596 | 519 | 630 | 447 | 59 | 2.2k | |
| Juan Putra | 838 | 390 | 559 | 384 | 66 | 1.9k | |
| Yukishige Yamada | 1198 | 642 | 150 | 526 | 46 | 2.3k | |
| Changping Wu | 1224 | 496 | 309 | 301 | 57 | 2.3k | |
| Romano Colombari | 1008 | 595 | 352 | 501 | 60 | 2.4k | |
| S Hirohashi | 591 | 542 | 863 | 582 | 54 | 2.5k | |
| Heung-Moon Chang | 1401 | 888 | 143 | 653 | 78 | 2.0k | |
| Gina M. Vaccaro | 1200 | 805 | 248 | 1104 | 50 | 2.2k | |
| Xiang‐Ming Lao | 992 | 293 | 409 | 268 | 56 | 2.1k |
All Works
Loading papers...